Business Description
LeMaitre Vascular Inc
NAICS : 339112
SIC : 3841
ISIN : US5255582018
Share Class Description:
STU:LHU: Ordinary SharesTotal Employee Number:
655Description
LeMaitre Vascular Inc. is a medical device company that develops, manufactures, and markets vascular devices used primarily by vascular surgeons, and to a lesser extent by cardiac, general, and neurosurgeons. Its portfolio includes branded products for open vascular and endovascular procedures, such as valvulotomes, carotid shunts, biologic patches, vascular grafts, embolectomy catheters, and balloon catheters. The company also provides human tissue cryopreservation services. LeMaitre sells its products to hospitals and clinics through a direct sales force in the United States and select international markets, supplemented by distributors elsewhere. It operates across the Americas, Europe, the Middle East, Africa, and Asia Pacific, with the Americas generating the largest share of revenue. Revenue comes mainly from product sales, with recurring sales driven by consumable and implantable devices used in surgical procedures.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.98 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | 1.89 | |||||
Interest Coverage | 14.88 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 7.2 | |||||
Beneish M-Score | -2.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.3 | |||||
3-Year EBITDA Growth Rate | 33.5 | |||||
3-Year EPS without NRI Growth Rate | 26.2 | |||||
3-Year FCF Growth Rate | 48.1 | |||||
3-Year Book Growth Rate | 12.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.09 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.48 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.43 | |||||
9-Day RSI | 46.77 | |||||
14-Day RSI | 43 | |||||
3-1 Month Momentum % | -14.02 | |||||
6-1 Month Momentum % | -26.18 | |||||
12-1 Month Momentum % | -6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.31 | |||||
Quick Ratio | 14.38 | |||||
Cash Ratio | 12.57 | |||||
Days Inventory | 297.99 | |||||
Days Sales Outstanding | 48.41 | |||||
Days Payable | 19.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.2 | |||||
Dividend Payout Ratio | 0.35 | |||||
3-Year Dividend Growth Rate | 17 | |||||
Forward Dividend Yield % | 1.26 | |||||
5-Year Yield-on-Cost % | 2.43 | |||||
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | -1.21 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.9 | |||||
Operating Margin % | 29.46 | |||||
Net Margin % | 25.03 | |||||
EBITDA Margin % | 38.27 | |||||
FCF Margin % | 27.92 | |||||
OCF Margin % | 31.39 | |||||
ROE % | 16.74 | |||||
ROA % | 10.73 | |||||
ROIC % | 26.07 | |||||
3-Year ROIIC % | 159.57 | |||||
ROC (Joel Greenblatt) % | 71.58 | |||||
ROCE % | 15.52 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 28.08 | |||||
Forward PE Ratio | 24.97 | |||||
PE Ratio without NRI | 30.72 | |||||
Shiller PE Ratio | 51.31 | |||||
Price-to-Owner-Earnings | 31.27 | |||||
PEG Ratio | 1.99 | |||||
PS Ratio | 7.23 | |||||
PB Ratio | 4.35 | |||||
Price-to-Tangible-Book | 5.69 | |||||
Price-to-Free-Cash-Flow | 25.74 | |||||
Price-to-Operating-Cash-Flow | 22.9 | |||||
EV-to-EBIT | 18.17 | |||||
EV-to-EBITDA | 16.26 | |||||
EV-to-Forward-EBITDA | 28.35 | |||||
EV-to-Revenue | 6.22 | |||||
EV-to-Forward-Revenue | 5.27 | |||||
EV-to-FCF | 22.45 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 2.12 | |||||
Price-to-DCF (Earnings Based) | 1.45 | |||||
Price-to-DCF (FCF Based) | 1.16 | |||||
Price-to-Median-PS-Value | 1.06 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.88 | |||||
Price-to-Graham-Number | 2.8 | |||||
| Price-to-Net-Current-Asset-Value | 6.88 | |||||
| Price-to-Net-Cash | 11.82 | |||||
Earnings Yield (Greenblatt) % | 5.52 | |||||
FCF Yield % | 4.06 | |||||
Forward Rate of Return (Yacktman) % | 18.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LeMaitre Vascular Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 225.03 | ||
| EPS (TTM) (€) | 2.407 | ||
| Beta | 0.3979 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.55 | ||
| Volatility % | 41.06 | ||
| 14-Day RSI | 43 | ||
| 14-Day ATR (€) | 1.620019 | ||
| 20-Day SMA (€) | 68.8 | ||
| 12-1 Month Momentum % | -6 | ||
| 52-Week Range (€) | 67 - 101 | ||
| Shares Outstanding (Mil) | 22.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LeMaitre Vascular Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LeMaitre Vascular Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 157 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-25 17:00 | In 157 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 156 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 46 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 45 days | ||
| 19(th) Annual Barrington Research Virtual Fall Investment Conference | 2026-09-22 | 68.50 (-0.72%) | ||
| Morgan Stanley 24(th) Annual Global Healthcare Conference | 2026-09-16 12:20 | 69.00 (-0.72%) | ||
| Wells Fargo 21(st) Annual Healthcare Conference | 2026-09-08 08:45 | 69.00 (+0.00%) | ||
| USD 0.250000 Cash Dividend | 2026-08-20 | 71.50 (+2.14%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 17:00 | 89.50 (+1.70%) |
Show
Entries
LeMaitre Vascular Inc Frequently Asked Questions
What is LeMaitre Vascular Inc(STU:LHU)'s stock price today?
The current price of STU:LHU is €69.00. The 52 week high of STU:LHU is €101.00 and 52 week low is €67.00.
When is next earnings date of LeMaitre Vascular Inc(STU:LHU)?
The next earnings date of LeMaitre Vascular Inc(STU:LHU) is 2026-11-06 Est..
Does LeMaitre Vascular Inc(STU:LHU) pay dividends? If so, how much?
The Dividend Yield %  of LeMaitre Vascular Inc(STU:LHU) is 1.2% (As of Today), Highest Dividend Payout Ratio of LeMaitre Vascular Inc(STU:LHU) was 0.48. The lowest was 0.25. And the median was 0.37. The  Forward Dividend Yield % of LeMaitre Vascular Inc(STU:LHU) is 1.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers